Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223307 · ClinicalTrials.gov registry record · Phase 2
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
A Phase 2 study of Liver Cancer and Liver Metastases, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT07223307: Recruiting Phase 2 study of Liver Cancer and Liver Metastases, sponsored by Stanford University.
NCT07223307 is a Phase 2 study of Liver Cancer and Liver Metastases that is actively recruiting participants, run by Stanford University. The registered enrollment target is 62 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223307, a Phase 2 study of Liver Cancer and Liver Metastases, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Primary Outcome
Overall survival will be defined as the time from treatment to death from any cause. Patients alive at the time of analysis will be censored at last follow-up.
Conditions Studied
Interventions
- RADIATION MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
What NCT07223307 shows while recruiting
NCT07223307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) is the first listed.
NCT07223307 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07223307 about?
NCT07223307 is a clinical study titled "REGULUS: MRI-guided Adaptive SABR for Liver Cancers". Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
What is the current status of trial NCT07223307?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2026-01-23. Estimated completion is 2030-01.
What conditions does trial NCT07223307 study?
This clinical trial studies the following conditions: Liver Cancer, Liver Metastases, Intrahepatic Cholangiocarcinoma, HCC.
What interventions are being tested in trial NCT07223307?
The interventions under investigation include: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT07223307?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223307 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223307's enrollment target sits among peer trials
62 35th of 78 higher than 44 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI